Geographic atrophy (GA) is one early and non-exudative symptom of AMD that has not yet received disease-specific treatment, despite the fact that anti-vascular endothelial growth factor (VEGF) therapy has significantly improved outcomes. Here, VEGFA is linked to age-related macular degeneration.